FDA Imposes Partial Hold On DBV Technologies' Phase III VITESSE Study

(RTTNews) - DBV Technologies' (DBVT) phase III study of modified Viaskin Peanut 250 µg patch, dubbed VITESSE, has been slapped with a partial clinical hold by the FDA. https://www.nasdaq.com/articles/fda-imposes-partial-hold-on-dbv-technologies-phase-iii-vitesse-study